SCHEMBL6656592

SCHEMBL6656592

CCCC(=O)Nc1ccc(CCN2N=C(c3ccc(OC)c(OC)c3)CCC2=O)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.60
PDE4B Q07343 11/20 0.58
PDE4D Q08499 3/20 0.53
PDE4A P27815 2/20 0.53
PDE4C Q08493 2/20 0.53
PDE3B Q13370 1/20 0.53
PDE3A Q14432 1/20 0.53
THRB P10828 2/20 0.48
POLB P06746 1/20 0.47
TP53 P04637 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6655641 0.95 LMNA (0.58) LMNAPDE4BPDE4DPDE4APDE4C
SCHEMBL6657115 0.94 LMNA (0.57) LMNAPDE4BPDE4DPDE4APDE4C
SCHEMBL6658933 0.93 PDE4B (0.59) LMNAPDE4BPDE4DPDE4APDE4C
SCHEMBL145191 0.91 PDE4B (0.66) LMNAPDE4BPDE4DPDE4APDE4C
SCHEMBL6654240 0.89 PDE4B (0.61) LMNAPDE4BPDE4DPDE4APDE4C
SCHEMBL6656013 0.89 PDE4B (0.61) LMNAPDE4BPDE4DPDE4APDE4C
SCHEMBL6654325 0.89 PDE4B (0.61) LMNAPDE4BPDE4DPDE4APDE4C
SCHEMBL6842351 0.88 PDE4B (0.58) LMNAPDE4BPDE4DPDE4APDE4C
SCHEMBL6654145 0.87 PDE4B (0.59) LMNAPDE4BPDE4DPDE4APDE4C
SCHEMBL6654148 0.87 PDE4B (0.59) LMNAPDE4BPDE4DPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
US-6531473-B2 Phosphodiesterase inhibitor; antiinflammatory agents MERCK PATENT GMBH (DE) 2003-03-11 US disclosed
US-20020111356-A1 Arylalkylpyridazinones MERCK KGAA (DE) 2002-08-15 US disclosed
US-6399611-B1 2-(4-ETHOXYCARBONYLAMINOBENZYL)-6-(3,4 -DIMETHOXYPHENYL)-2,3,4, 5-TETRAHYDROPYRIDAZIN-3-ONE OR ALTERNATELY BENZYL SUBSTITUTED COMPOUNDS; PHOSPHODIESTERASE IV AND TUMOUR NECROSIS FACTOR INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2002-06-04 US disclosed
EP-0738715-A2 Arylalkyl-pyridazinones MERCK PATENT GmbH (DE) 1996-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B LMNA 2603/4885PDE4B 4/4885PDE4D 12/4885
US-20020111356-A1 Arylalkylpyridazinones PDE4A, PDE5A, PDE2A LMNA 4187/4885PDE4B 8/4885PDE4D 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.